Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854581 · ClinicalTrials.gov registry record · Phase 4
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
A Phase 4 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00854581 is a Phase 4 study that was terminated before completion, run by University of Miami. The registered enrollment target is 13 participants.
The verdict
NCT00854581, a Phase 4 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1. Giving zidovudine, interferon alfa-2b, and PEG-interferon alfa-2b together may stimulate the immune system and slow down or keep the cancer cell from growing. PURPOSE: This clinical trial is studying how well giving zidovudine together with interferon alfa-2b and PEG-interferon alfa-2b works in treating patients with human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma.
Interventions
- DRUG Zidovudine
- DRUG Valproic Acid
- BIOLOGICAL PEG-interferon alfa-2b
- BIOLOGICAL Interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854581
The ClinicalTrials.gov registry entry for NCT00854581 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zidovudine is the first listed.
NCT00854581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00854581 about?
NCT00854581 is a clinical study titled "Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma". RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1. Giving zidovudine, interferon alfa-2b, and PEG-interferon alfa-2b together may stimulate the immune system and slow down or keep ...
What is the current status of trial NCT00854581?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2007-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00854581?
The interventions under investigation include: Zidovudine (DRUG), Valproic Acid (DRUG), PEG-interferon alfa-2b (BIOLOGICAL), Interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00854581?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.